Neal Gerber Eisenberg is pleased to support the ACI Annual Forum on Advanced Therapeutics, a gathering of leaders shaping the next generation of RNA, cell and gene therapies, and regenerative medicine. Whether you are joining us at the conference or exploring our capabilities more broadly, we invite you to learn more about our team and our experience advising innovators across the advanced therapeutics landscape.
Speaking Engagement
Michael B. Harlin, Partner
From Algorithms to Approvals: Harnessing AI to Accelerate Advanced Therapeutics While Managing Regulatory and IP Risks
March 26, 2026 · 9:00 a.m. ET
Michael Harlin will speak on how AI is accelerating the development of RNA, cell and gene therapies and regenerative medicines while raising new regulatory and intellectual property considerations. Joined by one other panelist, he will discuss AI enabled discovery, manufacturing innovation, regulatory perspectives, and key questions related to ownership and patent strategy for AI generated insights in advanced therapeutics.
Our Experience in Advanced Therapeutics
Our Life Sciences team works with innovators developing breakthrough modalities across RNA therapeutics, gene editing, regenerative medicine, and other emerging technologies. We help clients navigate the intersections of science, law, and business that define success in today’s advanced therapeutic landscape.
How We Support Innovators
Intellectual Property
- Patent strategy for RNA, cell and gene therapies, and regenerative technologies
- Protection of AI‑enabled discovery platforms and data‑driven inventions
- Portfolio development, prosecution, and global filing strategy
Regulatory & Compliance
- Guidance on FDA pathways for advanced biologics and novel modalities
- Considerations for AI‑enabled research and model transparency
- Risk assessment, data integrity, and compliance planning
Corporate & Transactional
- Licensing, research collaborations, and strategic partnerships
- Fundraising, venture financing, and investment readiness
- Structuring IP‑centered commercial and operational agreements
Litigation & Disputes
- Patent litigation involving biologics, biologic platforms, and genetic technologies
- Trade secret protection for laboratory, platform, and computational methods
- Freedom‑to‑operate, competitive landscape, and due‑diligence analyses
Learn More
Whether you are exploring opportunities in AI‑enabled drug discovery, developing next‑generation therapeutics, or scaling the business and regulatory structures around complex science, our team is here to help. We welcome the opportunity to discuss how we partner with life sciences companies to bring innovative therapies to market.
